Figure 6.
(a) Schematic of iDR-NC/neoantigen nanovaccines for synergistic tumor immunotherapy. The concurrent rolling circle replication (RCR) and rolling circle transcription (RCT) in the same solution producing tandem CpG and STAT3 shRNA, which were self-assembled into intertwining DNA-RNA MFs. (b) The above MFs were shrunk due to the presence of PPT-g-PEG and formed iDR-NCs, which was further loaded with tumor-specific neoantigen via hydrophobic interactions between hydrophobic PPT moieties and peptide antigens. (c) In immunocompetent mice, iDR-NCs/neoantigen complexes were delivered into APCs in draining LNs, which ultimately inhibited tumor growth by eliciting the strong and durable neoantigen-specific T cell responses. Adapted with permission from 90, copyright 2017 Nature Publishing Group (d) Schematic of the minimalist design of the PC7A nanovaccine. PC7A nanovaccine enhanced the antigen delivery, cross-presentation, and activated the STING pathway to robust T cell activation and to boost antitumor immunity for cancer immunotherapy. Adapted with permission from 91, copyright 2017 Nature Publishing Group.